Fermenting T cell stemness for cancer immunity

Area of Science:

• Immunology
• Microbiome research
• Cancer biology

Background:

• Gut microbial metabolites play a crucial role in modulating host immune responses, particularly in the context of cancer.
• The efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy can be influenced by the tumor microenvironment and systemic immunity.

Purpose of the Study:

• To investigate the role of specific gut microbial metabolites in enhancing anti-tumor immunity.
• To elucidate the mechanisms by which microbiota-derived compounds influence T cell function and responsiveness to immunotherapy.

Main Methods:

• Analysis of gut microbiota composition and metabolite production.
• In vivo and in vitro studies using mouse models of melanoma.
• Assessment of CD8+ T cell function, including stemness markers and effector functions.
• Investigation of the interaction between microbial metabolites and host transcription factors.

Main Results:

• Microbiota-derived butyrate was identified as a key metabolite promoting CD8+ T cell stemness.
• Butyrate, in cooperation with the transcription factor Foxo1, enhances the persistence and function of CD8+ T cells.
• This mechanism significantly improves the responsiveness of melanoma tumors to immune checkpoint inhibitors.

Conclusions:

• Gut microbial metabolite butyrate is essential for maintaining CD8+ T cell stemness and anti-tumor activity.
• Targeting the gut microbiome or its metabolites represents a promising strategy to augment cancer immunotherapy efficacy.
• The interplay between the gut microbiota, butyrate, Foxo1, and CD8+ T cells offers new therapeutic avenues for melanoma.